Document is current
Any future updates will be listed below
-
Authors
Yazaki, Shu
Kitadai, Rui
Momozawa, Yukihide
Yoshida, Teruhiko
Yamanaka, Takashi
Shiino, Sho
Yamauchi, Chisako
Harano, Kenichi
Saito, Motonobu
Hirotsu, Yosuke
Aiba, Hisaki
Hamamoto, Ryuji
Shimizu, Chikako
Shimomura, Akihiko
Shimoi, Tatsunori
Sudo, Kazuki
Yoshida, Masayuki
Sunami, Kuniko
Shiraishi, Yuichi
Kuchiba, Aya
Hori, Megumi
Katanoda, Kota
Takata, Sadaaki
Ogawa, Ayumi
Torasawa, Masahiro
Mochizuki, Akifumi
Shimada, Yoko
Hiranuma, Kengo
Fujii, Erisa
Hirata, Makoto
Yamashita, Yuji
Kogawa, Takahiro
Murata, Takeshi
Fujiwara, Saori
Miyagi, Yohei
Nakagomi, Hiroshi
Tachibana, Kazunoshin
Matsuda, Koichi
Murakami, Yoshinori
Tokunaga, Katsushi
Kawai, Yosuke
,
Ishibashi-Ueda, Hatsue
Tomita, Tsutomu
Noguchi, Michio
Takahashi, Ayako
Goto, Yu-ichi
Yoshida, Sumiko
Hattori, Kotaro
Matsumura, Ryo
Iida, Aritoshi
Maruoka, Yutaka
Gatanaga, Hiroyuki
Sugiyama, Masaya
Suzuki, Satoshi
Miyo, Kengo
Matsubara, Yoichi
Umezawa, Akihiro
Hata, Kenichiro
Kaname, Tadashi
Ozaki, Kouichi
Tokuda, Haruhiko
Watanabe, Hiroshi
Niida, Shumpei
Noiri, Eisei
Kitajima, Koji
Omae, Yosuke
Miyahara, Reiko
Shimanuki, Hideyuki
Kawai, Yosuke
Project, Biobank Japan
Omata, Masao
Ohtake, Tohru
Suto, Akihiko
Onishi, Tatsuya
Naito, Yoichi
Yamashita, Toshinari
Yonemori, Kan
Kohno, Takashi
Shiraishi, Kouya
-
Funding
Funding for this research was provided by:
Japan Agency for Medical Research and Development
Japan Society for the Promotion of Science
Grant-in-Aid for the Genome Research Project from Yamanashi Prefecture
Health Labour Sciences Research Grant
BRIDGE
National Cancer Center Research, and Development Fund
- License Information
-
More Information
Article History
Received: 22 May 2025
Accepted: 23 October 2025
First Online: 28 November 2025
Competing interests
: Masayuki Yoshida reported receiving personal fees from Roche Japan, Agilent Technologies, Chugai Pharma, Ono Yakuhin, MSD, and Daiichi Sankyo. He has participated on a Data Safety Monitoring Board or Advisory Board for Daiichi Sankyo. Kenichi Harano reported receiving grants from AstraZeneca, Chugai, Daiichi Sankyo, MSD, and Takeda, and personal fees from AstraZeneca, Chugai, Eisai, MSD, Taiho, and Takeda. He has participated on a Data Safety Monitoring Board or Advisory Board for AstraZeneca, Chugai, Daiichi Sankyo, Taiho, and Takeda. Takashi Yamanaka reported receiving personal fees from Daiichi Sankyo, Eli Lilly Japan, AstraZeneca, Chugai, Pfizer Japan, Kyowa Kirin, and Taiho. Kazunoshin Tachibana reported receiving grants from Chugai, Eisai, Taiho, Takeda, MSD, Daiichi Sankyo, Eli Lilly, Asahi Kasei, Nihon Kayaku, Kyowa Kirin, Astellas, and Maruho, and personal fees from Chugai, AstraZeneca, Pfizer, Eisai, Daiichi Sankyo, Eli Lilly, MSD, Kyowa Kirin, Teijin, Taiho, PDR Pharma, and Exact Sciences. Chikako Shimizu reported receiving personal fees from Chugai and has participated on a Data Safety Monitoring Board or Advisory Board for Daiichi Sankyo. Akihiko Shimomura reported receiving grants from Chugai Pharmaceutical, AstraZeneca, and Eisai, and personal fees from AstraZeneca, Daiichi Sankyo, Pfizer, Eli Lilly, MSD, Chugai Pharmaceutical, Nihon Medi-Physics, Taiho Pharmaceutical, and Exact Sciences. Takahiro Kogawa reported receiving grants from Eli Lilly, AstraZeneca, and Guardant Health; consulting fees from Daiichi Sankyo and Astellas Pharma; and personal fees from Daiichi Sankyo, Ono Pharma, Gilead Sciences, Astellas Pharma, Eisai, AstraZeneca, Taiho Pharma, and Chugai Pharma. He has received payment for expert testimony from Astellas Pharma and support for attending meetings from Pfizer and Eisai. He has participated on a Data Safety Monitoring Board or Advisory Board for Daiichi Sankyo, Ono Pharma, Gilead Sciences, Oncotherapy Sciences, Eisai, AstraZeneca, and Taiho Pharma. Tohru Ohtake reported receiving grants from Chugai, Eisai, Taiho, Takeda, Asahi Kasei, Daiichi Sankyo, Eli Lilly, Nihon Kayaku, and Kyowa Kirin, and personal fees from Chugai, Pfizer, AstraZeneca, Eisai, Daiichi Sankyo, Eli Lilly, Kyowa Kirin, Novartis, FUJIFILM Toyama Chemical, Johnson & Johnson, Asahi Kasei, Exact Sciences, Otsuka, and MSD. Tatsuya Onishi reported receiving grants from Daiichi Sankyo and Bayer Pharma, and personal fees from Daiichi Sankyo. Toshinari Yamashita reported receiving grants from Chugai, Taiho, Nippon Kayaku, Eli Lilly, Daiichi Sankyo, Pfizer, AstraZeneca, Seagen, MSD, Kyowa Kirin, Ono, Gilead Sciences, and Eisai, and personal fees from Chugai, Eisai, Daiichi Sankyo, Taiho, Nippon Kayaku, AstraZeneca, Kyowa Kirin, Pfizer, Eli Lilly, Novartis Pharma, and MSD. Yoichi Naito reported receiving grants from AbbVie, Ono, Daiichi Sankyo, Taiho, Pfizer, Boehringer Ingelheim, Eli Lilly, Eisai, AstraZeneca, Chugai, and Bayer, and personal fees from AstraZeneca, Eisai, Ono, Guardant, Takeda, Eli Lilly, Novartis, Pfizer, Chugai, PDR Pharma, Nihon Kayaku, Taiho, Bristol Myers Squibb, Bayer, Daiichi Sankyo, and MSD. Kan Yonemori reported receiving grants from MSD, Daiichi Sankyo, Merck Biopharma, AstraZeneca, Taiho, Pfizer, Novartis, Takeda, Chugai, Ono, Sanofi, Seagen, Eisai, Eli Lilly, Genmab, Boehringer Ingelheim, Kyowa Hakko Kirin, Nihon Kayaku, and Haihe; personal fees from Pfizer, Eisai, AstraZeneca, Eli Lilly, Takeda, Chugai, Fuji Film Pharma, PDR Pharma, MSD, Boehringer Ingelheim, Ono, Daiichi Sankyo, Bayer, Janssen, Astellas, Bristol Myers Squibb, Novartis, and Sanofi; and has participated on a Data Safety Monitoring Board or Advisory Board for Eisai, AstraZeneca, Sanofi, Genmab, Gilead, OncXerna, Takeda, Novartis, MSD, and Henlius. All remaining authors declare no conflicts of interest.
